246 related articles for article (PubMed ID: 16305402)
1. Dose sparing of CpG oligodeoxynucleotide vaccine adjuvants by nanoparticle delivery.
Diwan M; Elamanchili P; Cao M; Samuel J
Curr Drug Deliv; 2004 Oct; 1(4):405-12. PubMed ID: 16305402
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of immune responses by co-delivery of a CpG oligodeoxynucleotide and tetanus toxoid in biodegradable nanospheres.
Diwan M; Tafaghodi M; Samuel J
J Control Release; 2002 Dec; 85(1-3):247-62. PubMed ID: 12480329
[TBL] [Abstract][Full Text] [Related]
3. Induction of a balanced Th1/Th2 immune responses by co-delivery of PLGA/ovalbumin nanospheres and CpG ODNs/PEI-SWCNT nanoparticles as TLR9 agonist in BALB/c mice.
Ebrahimian M; Hashemi M; Maleki M; Abnous K; Hashemitabar G; Ramezani M; Haghparast A
Int J Pharm; 2016 Dec; 515(1-2):708-720. PubMed ID: 27989827
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable nanoparticle mediated antigen delivery to human cord blood derived dendritic cells for induction of primary T cell responses.
Diwan M; Elamanchili P; Lane H; Gainer A; Samuel J
J Drug Target; 2003; 11(8-10):495-507. PubMed ID: 15203918
[TBL] [Abstract][Full Text] [Related]
5. Robust mucosal and systemic responses against HTLV-1 by delivery of multi-epitope vaccine in PLGA nanoparticles.
Kabiri M; Sankian M; Sadri K; Tafaghodi M
Eur J Pharm Biopharm; 2018 Dec; 133():321-330. PubMed ID: 30408519
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation of Poly I:C and the natural phosphodiester CpG ODN enhanced the efficacy of a hyaluronic acid-modified cationic lipid-PLGA hybrid nanoparticle vaccine in TC-1-grafted tumors.
Liu C; Chu X; Yan M; Qi J; Liu H; Gao F; Gao R; Ma G; Ma Y
Int J Pharm; 2018 Dec; 553(1-2):327-337. PubMed ID: 30393151
[TBL] [Abstract][Full Text] [Related]
7. Time course study of the antigen-specific immune response to a PLGA microparticle vaccine formulation.
Wang Q; Tan MT; Keegan BP; Barry MA; Heffernan MJ
Biomaterials; 2014 Sep; 35(29):8385-93. PubMed ID: 24986256
[TBL] [Abstract][Full Text] [Related]
8. A protective allergy vaccine based on CpG- and protamine-containing PLGA microparticles.
Martínez Gómez JM; Fischer S; Csaba N; Kündig TM; Merkle HP; Gander B; Johansen P
Pharm Res; 2007 Oct; 24(10):1927-35. PubMed ID: 17541735
[TBL] [Abstract][Full Text] [Related]
9. Diaminosulfide based polymer microparticles as cancer vaccine delivery systems.
Geary SM; Hu Q; Joshi VB; Bowden NB; Salem AK
J Control Release; 2015 Dec; 220(Pt B):682-90. PubMed ID: 26359124
[TBL] [Abstract][Full Text] [Related]
10. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology.
San Román B; Irache JM; Gómez S; Tsapis N; Gamazo C; Espuelas MS
Eur J Pharm Biopharm; 2008 Sep; 70(1):98-108. PubMed ID: 18501572
[TBL] [Abstract][Full Text] [Related]
11. Carbonate Apatite Nanoparticles Act as Potent Vaccine Adjuvant Delivery Vehicles by Enhancing Cytokine Production Induced by Encapsulated Cytosine-Phosphate-Guanine Oligodeoxynucleotides.
Takahashi H; Misato K; Aoshi T; Yamamoto Y; Kubota Y; Wu X; Kuroda E; Ishii KJ; Yamamoto H; Yoshioka Y
Front Immunol; 2018; 9():783. PubMed ID: 29720976
[TBL] [Abstract][Full Text] [Related]
12. Cationic polymer modified PLGA nanoparticles encapsulating Alhagi honey polysaccharides as a vaccine delivery system for ovalbumin to improve immune responses.
Wusiman A; Gu P; Liu Z; Xu S; Zhang Y; Hu Y; Liu J; Wang D; Huang X
Int J Nanomedicine; 2019; 14():3221-3234. PubMed ID: 31123399
[No Abstract] [Full Text] [Related]
13. The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.
McCluskie MJ; Weeratna RD; Davis HL
Vaccine; 2001 Mar; 19(17-19):2657-60. PubMed ID: 11257405
[TBL] [Abstract][Full Text] [Related]
14. Characterization of Immune Responses to an Inactivated Avian Influenza Virus Vaccine Adjuvanted with Nanoparticles Containing CpG ODN.
Singh SM; Alkie TN; Abdelaziz KT; Hodgins DC; Novy A; Nagy É; Sharif S
Viral Immunol; 2016 Jun; 29(5):269-75. PubMed ID: 27077969
[TBL] [Abstract][Full Text] [Related]
15. PLGA (85:15) nanoparticle based delivery of rL7/L12 ribosomal protein in mice protects against Brucella abortus 544 infection: A promising alternate to traditional adjuvants.
Singh D; Somani VK; Aggarwal S; Bhatnagar R
Mol Immunol; 2015 Dec; 68(2 Pt A):272-9. PubMed ID: 26442664
[TBL] [Abstract][Full Text] [Related]
16. Co-encapsulated CpG oligodeoxynucleotides and ovalbumin in PLGA microparticles; an in vitro and in vivo study.
San Román B; Gómez S; Irache JM; Espuelas S
J Pharm Pharm Sci; 2014; 17(4):541-53. PubMed ID: 25579433
[TBL] [Abstract][Full Text] [Related]
17. A comparative study of the antigen-specific immune response induced by co-delivery of CpG ODN and antigen using fusion molecules or biodegradable microparticles.
Zhang XQ; Dahle CE; Weiner GJ; Salem AK
J Pharm Sci; 2007 Dec; 96(12):3283-92. PubMed ID: 17497736
[TBL] [Abstract][Full Text] [Related]
18. Delivery of an inactivated avian influenza virus vaccine adjuvanted with poly(D,L-lactic-co-glycolic acid) encapsulated CpG ODN induces protective immune responses in chickens.
Singh SM; Alkie TN; Nagy É; Kulkarni RR; Hodgins DC; Sharif S
Vaccine; 2016 Sep; 34(40):4807-13. PubMed ID: 27543454
[TBL] [Abstract][Full Text] [Related]
19. Surface-assembled poly(I:C) on PEGylated PLGA microspheres as vaccine adjuvant: APC activation and bystander cell stimulation.
Hafner AM; Corthésy B; Textor M; Merkle HP
Int J Pharm; 2016 Nov; 514(1):176-188. PubMed ID: 27863662
[TBL] [Abstract][Full Text] [Related]
20. Induction of systemic and mucosal immune responses by intranasal administration of alginate microspheres encapsulated with tetanus toxoid and CpG-ODN.
Tafaghodi M; Sajadi Tabassi SA; Jaafari MR
Int J Pharm; 2006 Aug; 319(1-2):37-43. PubMed ID: 16701972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
